Search 

We are a pharmaceutical startup in Memphis, Tennessee. Our focus is on pediatric drug delivery designs as we transform FDA approved therapeutic compounds into pediatric friendly drug delivery systems. We have designed several Epinephrine prodrugs to eliminate the need to use Epipen injections. We seek seed funding for organic synthesis, formulation development and CMC drug development.

to promote the business cooperation between Israel and Southwest China

iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.

One Top Chinese Pharma

JOT is a virtual company with its base operation in Jupiter, FL. JOT is in position to quickly come to market with a platform product effective to treat 12 or more indications including Alzheimer’s Disease. The proprietary patented product, JOTROL, is very safe, oral, naturally based and multi-functional. JOTROL will be very effective with high social and economic impact within a reasonable timeframe. Relationships have been developed with scientists at various institutions, such as University of Miami (“UM”), MIT, Harvard, Georgetown University and Murdoch Childrens Research Institute, AU. This setup has made it possible to gain access to laboratory work, scientific information, pre-clinical development and scientific expertise in an extremely cost effective and efficient way. JOT will conclude clinical trials by utilizing a contract manufacturer and Clinical Research Organizations, involvement by its scientific advisors as well as support from patient organizations thereby keeping its fixed overhead extremely low for a Biotech company. A Phase I trial is presently ongoing with results expected in Q1,2021. Two Phase II rare disease trials, are expected to be started in H2 of 2021 with possible accelerated approvals from FDA. Partial financing for those are expected to be received from NIH. A Phase II trial in Alzheimer’s is also planned to be executed in parallel. Financing for the Phase I study has been granted by NIA (National Institute of Aging). Financing for a larger Phase II study is also expected to be financed by a NIA consortium (up to $75 million). JOT is prepared to add a commercial organization to market its product in North America while out-licensing marketing and sales operations for the rest of the world.

Focus on cancer,intestinal disease

Kitov Pharma (NASDAQ:KTOV) is a clinical stage biopharmaceutical
company advancing first in class oncology therapies. We currently have one FDA
approved drug, Consensi™, and two oncology therapeutic candidates, CM-24 and NT-219:

• CM-24 is a clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with high potential to treat multiple oncology indications. CEACAM1 is associated with angiogenesis, is an
inter-cellular adhesion regulator and acts as a TIM-3 activator. High CEACAM1 expression is known to be associated with poor disease prognosis in a number of tumor types. Thus, blocking CEACAM1 with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms. In a phase I
clinical study, CM-24 demonstrated a good safety profile and promising efficacy signals. We are developing CM-24 in a clinical collaboration with Bristol
Myers-Squibb for Phase 1/2 trial combining CM-24 with nivolumab in NSCLC and pancreatic cancer patients expressing high CEACAM1 levels.

• NT-219 is a first-in-class, dual inhibitor small molecule targeting IRS 1/2 and STAT3, two key signal transducers that promote cancer drug resistance. In preclinical studies, NT-219 demonstrated outstanding
efficacy in preventing acquired resistance and reversing tumor resistance when administered as a monotherapy and in combination with various oncology therapies. We are initiating first-in-man clinical trials with NT219, both as monotherapy and in combination with cetuximab (Erbitux™), with plans to expand combination studies in patients with recurrent or metastatic SCCHN cancer during 2020.